Literature DB >> 978199

Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid.

K Menon, D Bieger, O Hornykiewicz.   

Abstract

D-Amphetamine (Amph) and p-chloroamphetamine (PCA) induced dose-dependent increases in oropharyngeal myocloniform twitch activity (MTA) in rats anesthetized with urethane. In doses of 80-120 mg/kg, gamma-hydroxybutyric acid (GHB) blocked Amph-induced MTA. The blockade was readily surmountable. Pretreatment with reserpine markedly enhanced the myoclonigenic effect of Amph and rendered it insensitive blockade by GHB, 160 mg/kg. PCA and tryptamine also effectively stimulated MTA, but unlike Amph were antagonized by low doses of the serotonin (5-HT) antagonist methysergide. In doses which blocked Amph, GHB failed to antagonize the myoclonigenic effect of PCA. It is concluded that: (a) the actions of Amph and PCA on MTA is less sensitive to GHB blockade than DA-mediated MTA; and (c) the GHB-Amph antagonism may be of a functional nature, i.e. result from a depression of the firing activity of DA neurons produced by GHB. Since reserpinization abolished the GHB effect on Amph-induced MTA, the functional integrity of granular DA binding and releasing mechanisms appears to be a pre-requisite for the antagonism between GHB and Amph.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 978199     DOI: 10.1007/BF01256508

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  18 in total

1.  ENHANCEMENT BY RESERPINE AND ALPHA-METHYL DOPA OF THE EFFECTS OF D-AMPHETAMINE UPON THE LOCOMOTOR ACTIVITY OF MICE.

Authors:  C B SMITH
Journal:  J Pharmacol Exp Ther       Date:  1963-12       Impact factor: 4.030

2.  [Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation].

Authors:  H LABORIT; F BUCHARD; G LABORIT; A KIND; B WEBER
Journal:  Agressologie       Date:  1960-11

3.  Influence of striatal dopamine receptor blockade on a bulbar motor reaction.

Authors:  D Bieger
Journal:  Neuropharmacology       Date:  1974-12       Impact factor: 5.250

4.  Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow.

Authors:  G Stock; T Magnusson; N E Andén
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  Studies on the biochemical mechanisms of the central effects of gamma-hydroxybutyric adic.

Authors:  M K Menon; R M Fleming; W G Clark
Journal:  Biochem Pharmacol       Date:  1974-02-15       Impact factor: 5.858

6.  Evidence that central nervous system depression by 1,4-butanediol in mediated through a metabolite, gamma-hydroxybutyrate.

Authors:  R H Roth; N J Giarman
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

7.  Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy.

Authors:  G K Aghajanian; R H Roth
Journal:  J Pharmacol Exp Ther       Date:  1970-10       Impact factor: 4.030

8.  The effect of sodium -hydroxybutyrate on the metabolism of dopamine in the brain.

Authors:  D A Hutchins; K S Rayevsky; D F Sharman
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

9.  Effect of -hydroxybutyrate on the release of monoamines from the rat striatum.

Authors:  G Bustos; R H Roth
Journal:  Br J Pharmacol       Date:  1972-04       Impact factor: 8.739

10.  Two types of monoamine liberation by chlorinated aralkylamines.

Authors:  A Pletscher; M Da Prada; G Bartholini; W P Burkard; H Bruderer
Journal:  Life Sci       Date:  1965-12       Impact factor: 5.037

View more
  2 in total

Review 1.  Neuropharmacologic correlates of deglutition: lessons from fictive swallowing.

Authors:  D Bieger
Journal:  Dysphagia       Date:  1991       Impact factor: 3.438

2.  Enkephalin-induced myoclonic twitches blocked by ergometrine and potentiated by haloperidol.

Authors:  M R Dzoljic; A J van der Lely; J B von Mourik
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.